Linfomas
GLUN
University of Melbourne
Melbourne, AustraliaPublicaciones en colaboración con investigadores/as de University of Melbourne (4)
2022
-
IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S387
-
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
The Lancet Oncology, Vol. 23, Núm. 8, pp. 1055-1065
-
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
Cancers, Vol. 14, Núm. 3
2018
-
Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety
Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2395-2404